{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:56Z","timestamp":1793109776014,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report a case of multi-organ injuries induced by tislelizumab in a lung squamous cell carcinoma (LUSC) patient. A 68-year-old man had undergone neoadjuvant chemotherapy with paclitaxel, carboplatin, and tislelizumab. He presented with a 1-month history of nausea and poor appetite after the second dose of therapy. During investigations, rhabdomyolysis, liver, kidney, and thyroid damage were detected. After multi-disciplinary consultation, multi-organ injuries related to ICIs (striated muscle, liver, kidney, and thyroid) were considered to result from cumulated irAEs induced by tislelizumab. The patient was treated with levothyroxine, methylprednisolone, intravenous immunoglobulins, and continuous renal replacement therapy. After treatment, the patient recovered and was discharged from the hospital. The patient presented with multiple organ damage, not single immunity treatment adverse reactions, relatively rare. In clinical work, irAEs are likely not a single-system organ disorder and many kinds of attention need to be combined with the risk of multi-system damage.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1508293","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:35:05Z","timestamp":1738650905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: Multi-organ injuries induced by tislelizumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Man","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non\u2013small-cell lung cancer","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2029414","article-title":"Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events","volume":"22","author":"Kujtan","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: a review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1039\/c8dt90088d","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"B6","unstructured":"Paclitaxel\n          \n          \n          LiverTox: Clinical and Research Information on Drug-Induced Liver Injury\n          \n          2012"},{"key":"B7","unstructured":"Carboplatin\n          \n          \n          LiverTox: Clinical and Research Information on Drug-Induced Liver Injury\n          \n          2012"},{"key":"B8","unstructured":"Pemetrexed and carboplatin\n          \n          2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B10","article-title":"A case of cholestatic drug-induced liver injury caused by chemotherapy with paclitaxel and cisplatin","volume":"16","author":"Qiu","year":"2019","journal-title":"Chin J Drug Appl Monit"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced Malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae Insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21791","article-title":"Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection","volume":"106","author":"Fardet","year":"2006","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13256-017-1272-9","article-title":"Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report","volume":"11","author":"Sokolova","year":"2017","journal-title":"J Med Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01655.x","article-title":"Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor","volume":"14","author":"Miki","year":"2007","journal-title":"Int J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1046330","article-title":"Case report: Rhabdomyolysis and kidney injury in a statin-treated hypothyroid patient\u2013kill two birds with one stone","volume":"9","author":"Chiang","year":"2022","journal-title":"Front Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/dhps.s333738","article-title":"A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management","volume":"13","author":"Safitri","year":"2021","journal-title":"Drug Healthc Patient Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48463","article-title":"Inflammatory myositis following statin use in a patient with untreated hypothyroidism","volume":"15","author":"Renteria","year":"2023","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8575-21","article-title":"Sinus node dysfunction co-occurring with immune checkpoint inhibitor-associated myocarditis","volume":"61","author":"Nishikawa","year":"2022","journal-title":"Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113559","article-title":"Insight of immune checkpoint inhibitor related myocarditis","volume":"143","author":"Pi","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.18295\/2075-0528.2796","article-title":"Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome","volume":"9","author":"Al-Hadi","year":"2009","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J Med Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0132-2","article-title":"Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation","volume":"8","author":"Charles","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592609","article-title":"Durable complete response in a melanoma patient with unknown primary, associated with sequential and severe multi-organ toxicity after a single dose of CTLA-4 plus PD-1 blockade: A case report","volume":"10","author":"Matull","year":"2020","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2050313X20972225","DOI":"10.1177\/2050313x20972225","article-title":"Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome","volume":"8","author":"Mintjens-Jager","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664809","article-title":"Immune-related multiple-organs injuries following ICI treatment with tislelizumab in an advanced non-small cell lung cancer patient: A case report","volume":"11","author":"Deng","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.799077","article-title":"Case report: glucocorticoid effect observation in a ureteral urothelial cancer patient with ICI-associated myocarditis and multiple organ injuries","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1053370","article-title":"Acetylcholine receptor binding antibody\u2013associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863297885240604111018","article-title":"Treatment of tislelizumab-induced toxic epidermal necrolysis and agranulocytosis: A case report and literature review","author":"Zhou","year":"2024","journal-title":"Curr Drug Saf"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e41781","DOI":"10.7759\/cureus.41781","article-title":"Multiorgan failure from nivolumab and ipilimumab: A case report and literature review","volume":"15","author":"Brazel","year":"2023","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e37562","DOI":"10.1097\/md.0000000000037562","article-title":"Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature","volume":"103","author":"Deng","year":"2024","journal-title":"Medicine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369531","article-title":"Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma","volume":"15","author":"Squicciarini","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879900","article-title":"Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: A multi-center study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00278-x","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1630619","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1508293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:51:16Z","timestamp":1749631876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1508293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1508293"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1508293","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1630619","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"article-number":"1508293"}}